Decrease of intracellular ROS by arbutin is associated with apoptosis induction and downregulation of IL-1β and TNF-α
Hajar Safari1, Ebrahim Zabihi2, Mahdi Pouramir2
1Student Research Committee, Babol University of Medical Sciences, Babol, Iran.
Abstract:
Increased reactive oxygen species (ROS) along with inflammation are involved in the prostate cancer (PCa). Therefore, this study was conducted to investigate the molecular mechanisms that were affected by arbutin as an antioxidant on prostate cancer cell line; LNCap. The intracellular ROS measurement confirmed that arbutin significantly (p < .05) decreased the ROS levels in a dose-dependent manner. Detection of cell death profile established that 1,000 μM of arbutin could remarkably induced apoptosis (p < .05), while tert-butyl hydroperoxide (tBHP) as ROS inducer prompted necrosis. In addition, 1,000 µM of arbutin successfully decreased expressions of IL-1β and TNF-α genes (p < .05). Furthermore, evaluation of the IL-1β protein level showed that arbutin could significantly decrease this cytokine (p < .05). In summary, reduction of ROS along with increasing apoptosis and decreasing expression of pro-inflammatory genes following arbutin treatment can open new visions in the treatment of prostate cancer using complementary medicine. PRACTICAL APPLICATIONS: Nowadays, arbutin as a glycosylated hydroquinone is available commercially in both natural and synthetic forms. Arbutin is of interest because of its skin-lightening effect, and used in cosmetic products for cutaneous hyperpigmentation. Arbutin inhibited tyrosinase in melanocytes competitively. Moreover, arbutin was able to attenuate oxidative stress and, its anti-inflammatory activities has been established. In addition, arbutin has represented useful activities for suppression of malignant melanoma development. In addition, arbutin exhibits several pharmacological effects, including antimicrobial, antihyperlipidemic, antihyperglycemic, and alpha amylase inhibitory effects. In this study, we showed its effect on prostate cancer in vitro. Therefore, it opens new insights in the complementary medicine that can maintain or improve human health.
Insights
Arbutin, an antioxidant, reduced reactive oxygen species (ROS) and inflammation in prostate cancer cells. This study suggests arbutin
Area of Science:
- Oncology
- Biochemistry
- Pharmacology
Background:
- Prostate cancer (PCa) is associated with increased reactive oxygen species (ROS) and inflammation.
- Arbutin, a natural antioxidant, has demonstrated anti-inflammatory and anti-melanoma properties.
- Investigating arbutin's effects on PCa provides potential complementary therapeutic strategies.
Purpose of the Study:
- To investigate the molecular mechanisms of arbutin's antioxidant effects on the LNCap prostate cancer cell line.
- To evaluate arbutin's impact on ROS levels, cell death, and inflammatory gene expression in PCa cells.
Main Methods:
- In vitro study using the LNCap prostate cancer cell line.
- Measurement of intracellular reactive oxygen species (ROS) levels.
- Assessment of cell death profiles (apoptosis and necrosis) and gene/protein expression of inflammatory markers (IL-1β, TNF-α).
Main Results:
- Arbutin significantly decreased intracellular ROS levels in a dose-dependent manner.
- Arbutin (1,000 μM) induced apoptosis, whereas tert-butyl hydroperoxide (tBHP) induced necrosis.
- Arbutin reduced the expression of pro-inflammatory genes (IL-1β, TNF-α) and IL-1β protein levels.
Conclusions:
- Arbutin exhibits antioxidant and anti-inflammatory effects in prostate cancer cells by reducing ROS and pro-inflammatory cytokines.
- Arbutin promotes apoptosis in PCa cells, suggesting a potential role in cancer therapy.
- These findings highlight arbutin's potential as a complementary medicine approach for prostate cancer treatment.
More Related Videos
19:44Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
Published on: May 30, 2012
10:16SorLA and CLC:CLF-1-dependent Downregulation of CNTFRα as Demonstrated by Western Blotting, Inhibition of Lysosomal Enzymes, and Immunocytochemistry
Published on: January 6, 2017
Related Concept Videos
The Intrinsic Apoptotic Pathway
The Extrinsic Apoptotic Pathway
